CAP-1002 is under clinical development by Capricor Therapeutics and currently in Phase II for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase II drugs for Congestive Heart Failure (Heart Failure) have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CAP-1002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAP-1002 is under development for the treatment of pulmonary arterial hypertension, advanced heart failure, Duchenne muscular dystrophy, ischemic heart disease. CDCs are delivered by intravenous and intracoronary infusion. The drug candidate is allogeneic cardiosphere-derived stem cells (CDCs). The drug candidate is developed based on CDC technology. It was also under development for the treatment of dilated cardiomyopathy, myocardial infarction, cardiomyopathy and ischemic left ventricular dysfunction, coronavirus disease 2019 (COVID-19). The drug candidate is a new molecular entity (NME).
Capricor Therapeutics overview
Capricor Therapeutics (Capricor) is a biotechnology company that focuses on the development and commercialization of biological therapies for the treatment of duchenne muscular dystrophy (DMD) and other rare disorders. The company pipeline product includes CAP-1002 is an allogeneic cardiosphere-derived cell product for the treatment of adult cardiology indications. Capricor technology comprises CAP-2003 for clinical development. The company is developing its exosome technologies as a next generation platform in a variety of diseases. The company offers research programs on cell therapy, natriuretic peptides and exosome platforms. It also conducts clinical trials for the development of novel therapeutics to prevent and treat cardiac and other serious medical conditions. Capricor is headquartered in San Diego, California, the US.
For a complete picture of CAP-1002’s drug-specific PTSR and LoA scores, buy the report here.